- Home
- EHI vs CBIO Comparison
EHI vs CBIO Comparison
Compare EHI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHI
- CBIO
- Stock Information
- Founded
- EHI 2003
- CBIO 2003
- Country
- EHI United States
- CBIO United States
- Employees
- EHI N/A
- CBIO N/A
- Industry
- EHI Investment Managers
- CBIO
- Sector
- EHI Finance
- CBIO
- Exchange
- EHI Nasdaq
- CBIO Nasdaq
- Market Cap
- EHI 192.4M
- CBIO 208.8M
- IPO Year
- EHI N/A
- CBIO N/A
- Fundamental
- Price
- EHI $6.39
- CBIO $13.21
- Analyst Decision
- EHI
- CBIO Strong Buy
- Analyst Count
- EHI 0
- CBIO 5
- Target Price
- EHI N/A
- CBIO $25.60
- AVG Volume (30 Days)
- EHI 44.5K
- CBIO 98.1K
- Earning Date
- EHI 01-01-0001
- CBIO 11-06-2025
- Dividend Yield
- EHI 11.54%
- CBIO N/A
- EPS Growth
- EHI N/A
- CBIO N/A
- EPS
- EHI N/A
- CBIO N/A
- Revenue
- EHI N/A
- CBIO N/A
- Revenue This Year
- EHI N/A
- CBIO N/A
- Revenue Next Year
- EHI N/A
- CBIO N/A
- P/E Ratio
- EHI N/A
- CBIO N/A
- Revenue Growth
- EHI N/A
- CBIO N/A
- 52 Week Low
- EHI $6.00
- CBIO $9.81
- 52 Week High
- EHI $7.75
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- EHI 43.05
- CBIO 58.90
- Support Level
- EHI $6.32
- CBIO $12.80
- Resistance Level
- EHI $6.40
- CBIO $12.84
- Average True Range (ATR)
- EHI 0.04
- CBIO 0.54
- MACD
- EHI 0.01
- CBIO 0.09
- Stochastic Oscillator
- EHI 55.24
- CBIO 92.13
About EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Financials, Energy, Communication energy, Industrials, materials, and others.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.